Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells

Journal of Immunology

Volumn 166, Issue 8, 2001, Pages 5250-5257

  Bonini, C ^a   Lee, S P ^a   Riddell, S R ^a   Greenberg, P D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN GP 39; LIPOPOLYSACCHARIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIGEN PRESENTATION; ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 0035871844     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.8.5250     Document Type: Article

References (55)

1. Dendritic cells and the control of immunity
2. + T-helper and a T-killer cell
3. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
4. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
5. Immunology: Licence to kill
6. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
7. Activation of human dendritic cells through CD40 cross-linking
8. The many roles of CD40 in cell-mediated inflammatory responses
9. Endocytosis by antigen presenting cells: Dendritic cells are as endocytically active as other antigen presenting cells
10. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
11. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
12. Dendritic cells as immunogens for human CTL responses
13. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine
14. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion
15. Role for intracellular proteases in the processing and transport of class II HLA antigens
16. The binary logic of antigen processing and presentation to T cells
17. Engineering a novel pathway for MHC class II presentation of HPV-16 E7
18. Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy
19. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
20. Lysosome-associated membrane protein-1 mediated targeting of HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class-II restricted T cells
21. The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway
22. + cytotoxic T lymphocytes: A novel approach to vaccine design
23. Lysosomal membrane glycoproteins
24. Glycoproteins of the lysosomal membrane
25. Identification of two lysosomal membrane glycoproteins
26. Accumulation of membrane glycoproteins in lysosomes requires a tyrosine residue at a particular position in the cytoplasmic tail
27. The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein I
28. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones
29. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA
30. Vaccinia virus immune evasion
31. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
32. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
33. Developmental regulation of MHC class II transport in mouse dendritic cells
34. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
35. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
36. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
37. The induction of tolerance by dendritic cells that have captured apoptotic cells
38. Inhibition of dendritic cell maturation by herpes simplex virus
39. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells
40. Trypanosoma cruzi infects human dendritic cells and prevents their maturation: Inhibition of cytokines, HLA-DR, and costimulatory molecules
41. + T cells
42. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity
43. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells
44. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
45. Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum
46. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell mediated lysis
47. Trimming of antigenic peptides in an early secretory compartment
48. Risk factors for cytomegalovirus infection after human marrow transplantation
49. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand?
50. Deficient cellular immunity: Finding and fixing the defects
51. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection
52. Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus
53. + virus-specific cytotoxic T lymphocytes
54. Melanoma vaccines
55. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus